 |
PDBsum entry 2oay
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Immune system,hydrolase inhibitor
|
PDB id
|
|
|
|
2oay
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
282:21100-21109
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease.
|
|
L.Beinrohr,
V.Harmat,
J.Dobó,
Z.Lörincz,
P.Gál,
P.Závodszky.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
C1 inhibitor, a member of the serpin family, is a major down-regulator of
inflammatory processes in blood. Genetic deficiency of C1 inhibitor results in
hereditary angioedema, a dominantly inheritable, potentially lethal disease.
Here we report the first crystal structure of the serpin domain of human C1
inhibitor, representing a previously unreported latent form, which explains
functional consequences of several naturally occurring mutations, two of which
are discussed in detail. The presented structure displays a novel conformation
with a seven-stranded beta-sheet A. The unique conformation of the C-terminal
six residues suggests its potential role as a barrier in the active-latent
transition. On the basis of surface charge pattern, heparin affinity
measurements, and docking of a heparin disaccharide, a heparin binding site is
proposed in the contact area of the serpin-proteinase encounter complex. We show
how polyanions change the activity of the C1 inhibitor by a novel
"sandwich" mechanism, explaining earlier reaction kinetic and
mutagenesis studies. These results may help to improve therapeutic C1 inhibitor
preparations used in the treatment of hereditary angioedema, organ transplant
rejection, and heart attack.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 6.
FIGURE 6. Showcase of mutations. A, studies failed to
detect any effect of the V458M polymorphism, although the
conserved hydrophobic core (around strands s2B, s3B, and s4B) is
involved (53). The reason is that the side chain of Met^458
(space-filled) sits in the biggest cavity of rC1-inh (orange
cloud); hence, spatial differences are tolerated. B, the A436T
mutation affects a residue whose side chain becomes buried upon
RCL incorporation. Similar mutants of other serpins usually
result in cleavable noninhibitory serpins, because loop
insertion is hindered. Unexpectedly, the A436T mutant C1-inh is
found predominantly in noncleavable loop-inserted forms (51). In
the modeled mutant structure, the side chain of Thr^436 forms a
novel hydrogen bond network with the side chain of His^421 and
the backbone of Gln^422. This makes the RCL-inserted protein
more stable.
|
 |
Figure 7.
FIGURE 7. Different mechanisms of the polyanion
potentiation of serpins. Serpins are shown as ellipses,
proteinases as circles, and polyanions as lines in this
schematic representation. Charged binding regions on proteins
are marked with black and charge signs. A, the most prominent
type of serpin activation by the "bridging" mechanism is
depicted (19, 20). Antithrombin binds tightly to a specific site
on the heparin chain. Thrombin binds to the same chain, but with
lower affinity. Only thrombin diffuses one-dimensionally toward
antithrombin until the encounter. Even then, they bind to
different segments on heparin. B, the similar "co-occupation"
mechanism proposed for protein C inhibitor is shown (29).
Protein C inhibitor and protein C bind to the same polyanion
chain, but neither binds with high affinity. Both proteins
migrate along the chain until the encounter. In the Michaelis
complex, they bind to the same site on the polyanion. C, the
"sandwich" mechanism is shown. C1-inh binds a short polyanion
with low affinity. Binding neutralizes surface charge at a
specific region. Proteinase is now attracted to this surface,
which happens to be the contact site in the encounter complex.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2007,
282,
21100-21109)
copyright 2007.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Bygum,
C.R.Fagerberg,
D.Ponard,
N.Monnier,
J.Lunardi,
and
C.Drouet
(2011).
Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency.
|
| |
Allergy,
66,
76-84.
|
 |
|
|
|
|
 |
R.Wallis,
D.A.Mitchell,
R.Schmid,
W.J.Schwaeble,
and
A.H.Keeble
(2010).
Paths reunited: Initiation of the classical and lectin pathways of complement activation.
|
| |
Immunobiology,
215,
1.
|
 |
|
|
|
|
 |
G.M.Keating
(2009).
Human C1-esterase inhibitor concentrate (Berinert).
|
| |
BioDrugs,
23,
399-406.
|
 |
|
|
|
|
 |
L.Yang,
M.F.Sun,
D.Gailani,
and
A.R.Rezaie
(2009).
Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.
|
| |
Biochemistry,
48,
1517-1524.
|
 |
|
|
|
|
 |
M.Cugno,
A.Zanichelli,
F.Foieni,
S.Caccia,
and
M.Cicardi
(2009).
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
|
| |
Trends Mol Med,
15,
69-78.
|
 |
|
|
|
|
 |
T.A.Murray-Rust,
F.K.Kerr,
A.R.Thomas,
T.Wu,
T.Yongqing,
P.C.Ong,
N.S.Quinsey,
J.C.Whisstock,
I.C.Wagenaar-Bos,
C.Freeman,
and
R.N.Pike
(2009).
Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1.
|
| |
Biochem J,
422,
295-303.
|
 |
|
|
|
|
 |
A.E.Davis,
P.Mejia,
and
F.Lu
(2008).
Biological activities of C1 inhibitor.
|
| |
Mol Immunol,
45,
4057-4063.
|
 |
|
|
|
|
 |
J.Dobó,
V.Harmat,
E.Sebestyén,
L.Beinrohr,
P.Závodszky,
and
P.Gál
(2008).
Purification, crystallization and preliminary X-ray analysis of human mannose-binding lectin-associated serine protease-1 (MASP-1) catalytic region.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun,
64,
781-784.
|
 |
|
|
|
|
 |
L.Varga,
G.Széplaki,
J.Laki,
A.Kocsis,
K.Kristóf,
P.Gál,
Z.Bajtay,
J.Wieslander,
M.R.Daha,
P.Garred,
H.O.Madsen,
G.Füst,
and
H.Farkas
(2008).
Depressed activation of the lectin pathway of complement in hereditary angioedema.
|
| |
Clin Exp Immunol,
153,
68-74.
|
 |
|
|
|
|
 |
M.Cicardi,
L.C.Zingale,
A.Zanichelli,
D.L.Deliliers,
and
S.Caccia
(2007).
The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema.
|
| |
Expert Opin Pharmacother,
8,
3173-3181.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |